A

AbbVie

Global biopharmaceutical company developing medicines

Senior Director - Global Assistant Controller & Finance Operations

Full-TimeUpdated on 10/23/2026
$206.5k - $393k/yr+ Long-term incentive program
Expert
Bachelor's, MBA
Irvine, CA, USA
HybridEmployees work in a hybrid mode.
AccountingFinancial Accounting

About the job

Requirements
  • At least 15 years of progressive accounting or finance experience.
  • A bachelor's degree in Accounting or Finance.
  • Experience leading and motivating a team in a dynamic business environment to achieve results and deliverables on time.
  • Experience leading the finance organization of a business unit and demonstrating enterprise leadership.
  • Pharmaceutical or consumer goods commercial finance experience and knowledge of the financial planning process.
  • Ability to solve business problems by identifying issues and collecting, analyzing, and interpreting related data.
  • Experience supporting senior operating management, with executive presence and the ability to challenge the status quo while building relationships.
  • Experience working independently and in team environments and integrating activities across multiple functions.
Responsibilities
  • Lead monthly, quarterly, and annual global close and reporting processes for Allergan Aesthetics, ensuring accurate and timely reporting of financial results in accordance with GAAP and Global and Corporate reporting requirements.
  • Develop effective reporting, monitor performance, and support contingency plan development as needed to deliver results with clear and concise commentary.
  • Coordinate US and pricing audit cycles with external and internal audit teams and implement audit recommendations by their due dates, as applicable.
  • Enhance internal controls in the US, strengthen the US internal control environment, and ensure financial results comply with AbbVie financial policies, SOX, and GAAP.
  • Lead monthly Governance reviews and identify key topics to highlight to the Vice President, Commercial Controller, and Senior Vice President, Corporate Controller.
  • Lead global planning processes (Plan, LBE, and LRP), integrating sales forecasts, pricing, and investment resourcing accurately and on time, and ensuring senior management input meets Business Unit, Global, and Corporate deadlines and deliverables.
  • Coordinate Business Unit timelines, requirements, targets, financial presentations, and financial results for planning requirements.
  • Ensure financial planning and reporting deliverables are accurate and clear for Executive-level review and approval.
  • Provide analyses for ad hoc and special-project business presentations that illuminate key business drivers and help senior management adapt strategies to short- and long-term objectives.
  • Lead intangible asset valuation analytics, partnering with Commercial and R&D business leaders to provide insights on brand dynamics, decision points, and forecast-assumption sensitivities.
  • Lead quarterly Investor Relations reporting for Allergan Aesthetics and shape the narrative for external reporting.
  • Lead US Aesthetics Pricing and partner with the US Aesthetics business to implement strategic pricing strategies, including cooperation with Tx to mitigate Best Price impacts on Botox Tx.
  • Monitor and enhance controls to ensure pricing operations are accurate and complete, in cooperation with business teams.
  • Lead the US Aesthetics Concierge Procure-to-Pay organization.
  • Lead the Global Aesthetics Sales & Operations Planning (S&OP) organization.
  • Represent Aesthetics Finance in global Finance Transformation efforts, interfacing between Areas and the Corporate team; ensure current and future systems and tools meet organizational needs and drive change management for Aesthetics.
  • Communicate strategic vision, assess organizational design, establish and monitor Key Performance Indicators, and drive decision-making for deliverables.
  • Partner cross-functionally with Allergan Aesthetics Brand Teams, Customer Service, Operations (Manufacturing), Supply Chain, BTS, and Enterprise Finance Transformation leadership and teams to align and execute goals.
  • Build an effective network within Aesthetics to facilitate navigation and alignment in a complex matrix environment.
  • Lead and develop a team of approximately 30 professionals, including 8 direct reports.
  • Identify, nurture, and develop key talent for future leadership roles across AbbVie’s Aesthetics and Therapeutics organizations.
  • Identify future process improvements as a key member of the Aesthetics Finance leadership team.
  • Manage matrix relationships with Global/Corporate Finance, Internal/External Audit, and Therapeutics Finance.
Desired Qualifications
  • An MBA in Accounting or Finance and/or CPA.
  • A solid understanding of automated accounting and financial systems such as SAC, desktop productivity, and mainframe accounting applications.
  • A deep understanding of pharmaceutical and medical device pricing dynamics.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 24th, 2026
AbbVie wins FDA nod for at-home Skyrizi starts in Crohn's; sales boost seen after 60-90 days

AbbVie won US Food and Drug Administration (FDA) approval on October 23 for an at-home start to Skyrizi in adults with moderately to severely active Crohn's disease. Patients previously had to begin with intravenous infusions; they can now take the first doses at home with an on-body injector. By Week 12, 74% of patients new to advanced therapy reached clinical remission, against 27% on placebo. Johnson & Johnson's rival Tremfya won similar approval about 19 months earlier. Chief commercial officer Jeff Stewart said full paid access "will probably take 60 or 90 days" because insurers must approve the regimen. Sales impact should therefore come mostly after the fourth quarter. AbbVie reports third-quarter results on October 30. It guides for revenue of about $17.2 billion; Skyrizi's franchise sold $17.562 billion in 2025.

Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.